1) Functional compartmentalization of the plasma membrane of neurons by a unique acyl chain composition of
丂 phospholipids.
丂 Kuge H, Akahori K, Yagyu K, Honke K.
丂 J Biol Chem. 2014; 289:26783-26793 (IF: 4.600 )

3) Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)
丂 -chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
丂 Li TS, Yawata T, Honke K.
丂 Eur J Pharm Sci. 2014; 52:48-61

4) Segregation of lipid rafts revealed by the EMARS method using GPI-anchored HRP fusion proteins.
丂 Miyagawa-Yamaguchi A, Kotani N. Honke K.
丂 Trends Glycosci Glyc. 2014; 26:59-69 (review) (IF: 0.837) 丂丂丂丂丂

5) Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
丂 Karashima T, Komatsu T, Nishimura M, Kawada C, Kamada M, Inoue K, Udaka K, Kuroda N and Shuin T.
丂 Int J Urology. 21(7):702-6, 2014(IF:2.409) 丂丂丂丂丂

6) Genome Analysis of Pseudomonas aeruginosa Bacteriophage KPP23, Belonging to the Family Siphoviridae.
丂 Yamaguchi K, Miyata R, Shigehisa R, Uchiyama J, Takemura-Uchiyama I, Kato S, Ujihara T, Sakaguchi Y, Daibata M,
丂 Matsuzaki S.
丂 Genome Announc. 2014 May 22;2(3). pii: e00233-14.

11) In silico analysis of AHJD-like viruses, Staphylococcus aureus phages S24-1 and S13', and study of phage S24-1
丂 adsorption.
丂 Uchiyama J, Takemura-Uchiyama I, Kato S, Sato M, Ujihara T, Matsui H, Hanaki H, Daibata M, Matsuzaki S.
丂 Microbiologyopen. 2014 Apr;3(2):257-70. doi: 10.1002/mbo3.166. Epub 2014 Mar 4. IF(2014) 2.213 丂

12) Genomic and phylogenetic traits of Staphylococcus phages S25-3 and S25-4 (family Myoviridae, genus Twort-like
丂 viruses).
丂 Takemura-Uchiyama I, Uchiyama J, Kato S, Ujihara T, Daibata M, Matsuzaki S.
丂 Ann Microbiol. 64(3):1453-1456.2014. IF (2014)丂0.990 丂

13) Safety and efficacy of image-guided enzyme-targeting radiosensitization plus intraoperative radiotherapy for locally
丂 advanced unresectable pancreatic cancer.
丂 Nishioka A, Ogawa Y, Miyatake K, Tadokoro M, Nogami M, Hamada N, Kubota K, Kariya S, Kohsaki T, Saibara T,
丂 Okabayashi T, Hanazaki K.
丂 Oncol Lett. 8:404-8, 2014 (IF: 1.554) 丂

14) Hepatic arterial infusion chemotherapy by the fixed-catheter-tip method: Retrospective comparison of percutaneous
丂 left subclavian and femoral port-catheter system implantation.
丂 Matsumoto T, Yamagami T, Yoshimatsu R, Morishita H, Kitamura N, Sato O, Hasebe T.
丂 AJR. 202:211-5, 2014 (IF: 2.731) 丂

15) Venous sac embolization of pulmonary arteriovenous malformation: safety and effectiveness at mid-term follow-up.
丂 Kajiwara K, Urashima M, Yamagami T, Kakizawa H, Matsuura N, Matsuura A, Ohnari T, Ishikawa M, Awai K.
丂 Acta Radiol. 55:1093-8, 2014 (IF: 1.603) 丂

16) Basic fibroblast growth factor as potential stent coating material for endothelial cell proliferation.
丂 Kitamura N, Hasebe T, Matsumoto T, Hotta A, Suzuki T, Yamagami T, Terada H.
丂 J Atheroscler Thromb. 21:477-85, 2014 (IF: 2.733) 丂

17) Transarterial therapy of hepatocellular carcinoma fed by the right renal capsular artery.
丂 Ishikawa M, Yamagami T, Kakizawa H, Hieda M, Toyota N, Fukumoto W, Kajiwara K, Yoshimatsu R, Aikata H,
丂 Chayama K, Awai K.
丂 J Vasc Interv Radiol. 25:389-95, 2014 (IF: 2.409) 丂

18) Effectiveness of combined use of imprint cytological and histological examination in CT-guided tissue-core biopsy.
丂 Yamagami T, Yoshimatsu R, Kajiwara K, Ishikawa M, Matsumoto T, Kakizawa H, Toyoda N, Hasebe T, Awai K.
丂 Eur Radiol. 24: 1127-34, 2014 (IF: 4.014) 丂

19) Transcatheter arterial chemoembolization with an interventional-CT system for recurrent hepatocellular carcinoma
丂 after living donor liver transplantation.
丂 Yamagami T, Yoshimatsu R, Ishikawa M, Kajiwara K, Aikata H, Tashiro H, Kakizawa H, Toyoda N, Ohdan H, Awai K.
丂 Hepatogastroenterology. 61:1387-92, 2014 (IF: 0.928) 丂

20) Measurement of electron density and effective atomic number by dual-energy scan using a 320-detector computed
丂 tomography scanner with raw data-based analysis: a phantom study.
丂 Tatsugami F, Higaki T, Kiguchi M, Tsushima S, Taniguchi A, Kaichi Y, Yamagami T, Awai K.
丂 J Comput Assist Tomogr.38:824-7, 2014 (IF: 1.411) 丂

21) Multidetector computed tomography-based microstructural analysis reveals reduced bone mineral content and
丂 trabecular bone changes in the lumbar spine after transarterial chemoembolization therapy for hepatocellular
丂 carcinoma.
丂 Takasu M, Yamagami T, Nakamura Y, Komoto D, Kaichi Y, Tani C, Date S, Kiguchi M, Awai K.
丂 PLoS One. 2014 16;9(10):e110106. doi: 10.1371/journal.pone.0110106. eCollection 2014 (IF: 3.234) 丂

22) Early prediction of response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted
丂 imaging and gray-scale ultrasonography.
丂 Iwasa H, Kubota K, Hamada N, Nogami M, Nishioka A.
丂 Oncol Rep. 31(4):1555-60,2014 (IF: 2.301) 丂

23) Assessment of permanent brachytherapy combined with androgen deprivation therapy in an intermediate-risk
丂 prostate cancer group without a Gleason score of 4 + 3: a single Japanese institutional experience.
丂 Okihara K, Kobayashi K, Iwata T, Naitoh Y, Kamoi K, Kawauchi A, Yamada K, Miki T.
丂 Int J Urol. 21(3):271-6, 2014 (IF: 2.409)

挊彂

1) Honke, K.:
丂UDP-Gal:ceramide galactosyltransferase (UGT8). in 乬Handbook of Glycosyltransferases and Related Genes 2nd Ed乭
丂 (Eds. by Taniguchi, N., Honke, K. Fukuda, M., Narimatsu, H., Yamaguchi, Y., and Angata, T.), Springer, pp 131-140,
丂 2014.

2) Honke, K.:
丂UDP-GalNAc: 兝-1,3-N-acetylgalactosaminyltransferase 1 (B3GALNT1). in 乬Handbook of Glycosyltransferases and
丂Related Genes 2nd Ed乭
丂 (Eds. by Taniguchi, N., Honke, K. Fukuda, M., Narimatsu, H., Yamaguchi, Y., and Angata, T.), Springer, pp 447-453,
丂 2014.

3) Honke, K.:
丂Globoside 兛-1,3-N-acetylgalactosaminyltransferase 1 (GBGT1). in 乬Handbook of Glycosyltransferases and Related
丂Genes 2nd Ed乭
丂(Eds. by Taniguchi, N., Honke, K. Fukuda, M., Narimatsu, H., Yamaguchi, Y., and Angata, T.), Springer, pp. 455-461,
丂2014.

4) Honke, K.:
丂Galactose-3-O-sulfotransferase-1-4 (GAL3ST1-4). in 乬Handbook of Glycosyltransferases and Related Genes 2nd Ed乭
丂(Eds. by Taniguchi, N., Honke, K. Fukuda, M., Narimatsu, H., Yamaguchi, Y., and Angata, T.), Springer, pp 1123-
丂1134, 2014.

5) Elbein, A. D. and Honke, K.:
丂Chapter 27. Complex carbohydrates: Glycoproteins. in 乬Medical Biochemistry 4th Ed乭
丂(Eds. by Baynes, J.W. and Dominiczak, M.H.), pp 353-368, Saunders Elsevier, 2014.

6) Elbein, A. D. and Honke, K.:
丂Chapter 28. Complex lipids. in 乬Medical Biochemistry 4th Ed乭
丂(Eds. by Baynes, J.W. and Dominiczak, M. H.), pp 369-379, Saunders Elsevier, 2014.

7) Honke, K. and Kotani, N.:
丂EMARS Method: A tool for molecular interactome. in 乬Glycoscience: Biology and Medicine乭
丂(Eds. by Taniguchi, N., Endo, T., Hart G.W., Seeberger, P.H., and Wong, C.-H.), Springer, pp 17-23, 2014.

8) Matsuzaki S, Uchiyama J,丂Takemura-Uchiyama I, and Daibata M.
丂Chapter 10. Phage therapy: experiments using animal infection models. Phage Therapy.
丂Current Research and Applications. Editors: Jan Borysowski, Ryszard Miedzybrodzki, Andrzej Gorski (eds.), pp237-256,
丂Caister Academic Press, Norfork, UK. 2014.

1) EP 2434014 (EP)
丂 乬HLA-binding peptide, precursor thereof, DNA fragment and recombinant vector encoding the same乭
丂 Tomoya Miyakawa, Keiko Udaka
丂 2014.12.10

2) 摿嫋戞5648927崋
丂 乽HLA寢崌惈儁僾僠僪丄偦偺慜嬱懱丄偦傟傪僐乕僪偡傞DNA抐曅偍傛傃慻傒姺偊儀僋僞乕乿
丂 敪柧恖丗媨愳抦栫丒塅崅宐巕
丂 2014.11.21

3) 摿嫋戞5633825崋
丂 乽嵶朎彎奞惈T嵶朎偺桿摫曽朄丄嵶朎彎奞惈T嵶朎偺桿摫嵻丄偍傛傃偦傟傪梡偄偨堛栻慻惉暔偍傛傃儚僋僠儞乿
丂 敪柧恖丗媨愳抦栫丒塅崅宐巕
丂 2014.10.24

4) 摿嫋戞5614659崋乮擔杮崙乯
丂 乽HLA寢崌惈儁僾僠僪丄偦偺慜嬱懱丄偦傟傪僐乕僪偡傞DNA抐曅偍傛傃慻傒姺偊儀僋僞乕乿
丂 敪柧幰丗媨愳抦栫丄塅崅宐巕丄庢摼擔丗2012.12.4

弌婅

1) 摿婅2014-046922丂乽墿怓僽僪僂媴嬠傪専弌偡傞曽朄丄墿怓僽僪僂媴嬠應掕梡儊儞僽儗儞丄媦傃墿怓僽僪僂媴嬠應掕梡僉僢僩乿
丂 敪柧幰:撪嶳弤暯丄撪嶳埳戙丄壴栘廏柧丄徏堜廏恗丄戝敤夒揟丄徏嶈栁揥 弌婅恖丗巐崙TLO丄崙撪摿嫋

2) PCT/JP2014/058711
丂 N-僌儕僐僔儖巁傾儈僪傾儈僲巁-妀巁桿摫懱偍傛傃偦偺惢憿曽朄
丂 弌婅恖丗丂崙棫戝妛朄恖崅抦戝妛
丂 敪柧幰丗丂杮壠岶堦丄彫捨擔媑嶰丄曅壀惓揟丄暉堜愮弔
丂 弌婅擔丗2014擭3寧27擔
丂 婎慴弌婅丗摿婅2013-073744乮2013擭3寧29擔乯

3) 摿婅2014-048194
丂 傾儈僲傾僔儖僰僋儗僆僠僪壔崌暔偺惢憿曽朄
丂 弌婅恖丗丂崙棫戝妛朄恖崅抦戝妛
丂 敪柧幰丗丂杮壠岶堦丄彫捨擔媑嶰丄曅壀惓揟丄暉堜愮弔
丂 弌婅擔丗丂暯惉26擭3寧11擔

1) Nagano H, Miura H, Takeuchi Y, Terayama K, Tanaka O, Yoshimatsu R, Ichijo Y, Tanaka T, Yamagami T. Nagano,
丂 Miura.
丂 Medium infused radiofrequency ablation in lung: investigation using a swine model.
丂 ECR 2014, Viena, 2014

2) Takezawa K, Miura H, Takeuchi Y, Terayama K, Tanaka O, Yoshimatsu R, Yamagami T.
丂 Incidence and Risk Factors of Pneumothorax and Pulmonary Hemorrhage after CT-guided Lipodol Marking Before
丂 Video-assisted Thoracoscopic Surgery for Small Pulmonary Lesions.
丂 ECR 2014, Viena, 2014

3) Yamagami T, Yoshimatsu R, Iida M, Tanitame N, Ono C, Kajiwara K, Waki K, Tsuji K, Awai K.
丂 Balloon-occluded retrograde transvenous obliteration of gastric varix with multiple draining veins performed with
丂 temporal occlusion of the pericardiacophrenic vein with a micro-balloon.
丂 Annual Meeting and Postgraduate Course of the Cardiovascular and Interventional Radiological Society of Europe
丂 2014, Glasgow, UK.2014

4) Kajiwara K, Yamagami T, Yoshimatsu R, Ishikawa M, Awai K.
丂 Percutaneous CT fluoroscopy-guided abdominal and pelvic abscess drainage: comparison of one-step and Seldinger
丂 techniques.
丂 Annual Meeting and Postgraduate Course of the Cardiovascular and Interventional Radiological Society of Europe
丂 2014, Glasgow, UK.2014

5) Saeki K, Yamagami T, Misezaki Y, Kono S, Ishifuro M, Awai K.
丂 Usefulness of the max entrance skin dose measured with CareMonitor irrespective of changes in the geometry of the
丂 angiography system.
丂 RSNA 2014 Scientific posters, Chicago, USA.2014

6) Ishikawa M, Horikawa M, Uchida BT, Timmermans HA, Kaufman JA, Awai K, Yamagami T.
丂 A mixture of n-butyl cyanoacrylate, Lipiodol and ethanol under flow control using an arteriovenous malformation
丂 (AVM) model, is it useful for embolization.
丂 RSNA 2014 Scientific posters, Chicago, USA.2014

7) Higaki T, Kaichi Y, Fujioka C, Kiguchi M, Tsushima S, Awai K, Yamagami T, Tatsugami F.
丂 Measurement of electron density using raw data-based dual-energy computed tomography.
丂 Phantom study. RSNA 2014 Educational Exhibits, Chicago, USA.2014

8) Nogami M, KataokaY, Iwasa H, Kohsaki S, Akagi N and Ogawa Y.
丂 18F FDG PET/CT after diuretic for the patients with bladder cancer: Correlation of SUV on PET with ADC on MRI.
丂 Society of Nuclear Medicine 2014. St. Louis, USA. 2014/6/7-11

9) Nogami M, Aoyama N, Iwasa H, Kataoka Y, Tadokoro M, Kohsaki S, Kubota K, Nishioka A, and Ogawa Y.
丂 Dual-time-point FDG-PET/CT for invasive ductal carcinoma of the breast: Correlation of temporal changes in
丂 volumetric lesion glycolysis with pathological prognostic factors and axillary lymph node status.
丂 European Association of Nuclear Medicine 2014. Gothenburg, Sweden. 2014/10/18-22

10) Nogami M, Iwasa H, Kohsaki S, Tadokoro M, Tamura T, Kubota K, Morio K, Akagi N and Nishioka A.
丂 Diuretic FDG PET/CT and diffusion weighted MR imaging for urothelial carcinoma: Comparison of SUV, ADC and
丂 pathological characteristics. 100th Radiological Society of North America Scientific Assembly and Annual Meeting.
丂 Chicago, USA. 2014/11/29-12/4

11) Tadokoro M, Miyaji T, Murata Y, Nishioka A, Ogawa Y.
丂 Tumor-Like Fat Distribution in the Left Ventricle Wall Causing Ventricular Fibrillation -A Case of Nodular Sclerosis in a
丂 14-year-old Boy.
丂 SCCT Hawaii 2014.Hawaii, USA. 2014/1/13-16

12) Yamanishi T, Tamura T, Oogi K, Nishimori M, Iwasa H, Miyatake K, Yamagami T.
丂 Early experience of detachable coil embolization of left subclavian artery for TEVAR with debranching.
丂 GEST Asia 2014. Tokyo, Japan, 2014/12/19-20

13) Aoyama N, Ogawa Y, Kubota K.
丂 Therapeutic Response to a New Enzyme-targeting Radiosensitization Treatment (KORTUC 2) in Patients with
丂 Recurrent Breast Cancer.
丂 AOCR2014(Asian Oseanian Congress of Radiology), Kobe, Japan, 2014/9/24-8

崙撪妛夛

1) 杮壠岶堦
丂 GPI-傾儞僇乕宆HRP梈崌僞儞僷僋幙偑偮偔傝弌偡枌旝彮娐嫬
丂 僔儞億僕僂儉亀摐嵔偑偮偔傝弌偡旝彫娐嫬偺僋儘乕僘傾僢僾亁戞87夞擔杮惗壔妛夛戝夛丄 暯惉26擭10寧18擔丄嫗搒

2) 徏嶈栁揥丄 撪嶳弤暯丄 撪嶳埳戙丄 懞忋夒彯丄 戝敤夒揟
丂 僶僋僥儕僆僼傽乕僕椕朄偺尰忬偲壜擻惈
丂 2014擭搙擔杮擾寍壔妛夛惣擔杮巟晹戝夛僔儞億僕僂儉 乽僼傽乕僕尋媶偺怴揥奐乿 HOTEL僌儔儞僨偼偑偔傟丒嵅夑戝妛杮彲僉儍
丂 儞僷僗丄 嵅夑丄2014.9.18-19.

3) 嶳忋戩巑
丂 惷柆寣愷嵡愷徢偵懳偡傞IVR
丂 戞17夞暷巕IVR尋媶夛丄暷巕丄2014

4) 嶳忋戩巑
丂 Venous thromboembolism偵懳偡傞IVR
丂 戞9夞IVR媄弍岎棳夛丄搶嫗丄2014

5) 嶳忋戩巑
丂 尋媶僥乕儅偼擔乆偺IVR徢椺偺拞偵愽傫偱偄傞
丂 戞43夞擔杮IVR妛夛憤夛儌乕僯儞僌僙儈僫乕: IVR椞堟偵偍偗傞僄價僨儞僗憂弌嵟怴偺尋媶惉壥傗憿塭嵻僩僺僢僋僗傪傆傑偊偰丄
丂 撧椙丄2014

6) 嶳忋戩巑
丂 娞庮釃偵懳偡傞IVR
丂 戞76夞峀搰娞娻徢椺専摙夛丄峀搰丄2014

7) 嶳忋戩巑
丂 惷柆寣愷嵡愷徢偵懳偡傞IVR
丂 戞62夞壀嶳寣娗憿塭丒Interventional Radiology尋媶夛丄壀嶳丄2014

8) 嶳忋戩巑
丂 栧柆埑槾恑徢偵懳偡傞IVR -B-RTO傪拞怱偵-
丂 拞崙娞幘姵帯椕 僙儈僫乕丄峀搰丄2014

9) 媑徏棞崄
丂 堛惷柆釒偵懳偡傞B-RTO
丂 戞28 夞拞崙巐崙IVR 尋媶夛丄壀嶳丄2014

曬摴

1) 暯惉26擭8寧9擔丂崅抦怴暦挬姧
丂 乽崅抦戝儕儞帀幙摿惈夝柧丂嵶朎枌撪僞儞僷僋幙傪惂屼乿

1) Perioperative intensive insulin therapy using an artificial endocrine pancreas with closed-loop glycemic control system:
丂 The effects of no hypoglycemia
丂 Hanazaki K, Kitagawa H, Yatabe T, Munekage M, Dabanaka K, Takezaki Y, Tsukamoto Y, Asano T, Kinoshita Y,
丂 Namikawa T.
丂 Am J Surg. 2014 207(6):935-941. (IF 2.291)

2) Application of an artificial pancreas for a liver transplant recipient.
丂 Hayashi H, Takamura H, Nakanuma S, Makino I, Tajima H, Fushida S, Hanazaki K, Ohta T.
丂 Exp Clin Transplant.. 2014 12(6):572-573 (IF 0.622)

3) IGF2BP3-mediated translation in cell protrusions promotes cell invasiveness and metastasis of pancreatic cancer.
丂 Taniuchi K, Furihata M, Hanazaki K, Saito M, Saibara T.
丂 Oncotarget. 2014 5(16):6832-6845. (IF 6.359)

4) Natural progression of a sporadic pheochromocytoma over 15 years.
丂 Taguchi T, Takao T, Terada Y.
丂 Endocrine. 49(2):572-573, 2014 .(IF:3.878)

5) Graves' dermopathy and acropachy.
丂 Taguchi T, Nakajima H, Terada Y.
丂 Endocrine. 49(1):296-297, 2014. (IF:3.878)

6) IgG4-related tubulointerstitial nephritis accompanied with cystic formation.
丂 Fukuhara H, Taniguchi Y, Matsumoto M, Kuroda N, Fukata S, Inoue K, Fujimoto S, Terada Y,Shuin T.
丂 BMC Urol. 2014 Jul 20;14:54. doi: 10.1186/1471-2490-14-54. (IF:1.413)

7) Serum levels of soluble urokinase plasminogen activator receptor in Japanese patients with chronic kidney disease.
丂Taniguchi Y, Shimamura Y, Horino T, Fujimoto S, Terada Y.
丂 Kidney Int. 86(1):209-10, 2014. (IF:8.563)

8) Images in clinical medicine. Subperiosteal bone resorption.
丂 Taguchi T, Terada Y.
丂 N Engl J Med. 370(21):e32, 2014.(IF:55.873)

9) Concentric-ring sign in adrenal hemorrhage.
丂 Taguchi T, Inoue K, Terada Y.
丂 Endocrine. 47(3):965-966, 2014. (IF:3.878)

10) Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice. a new
丂 model of systemic Lupus erythematosus.
丂 Yokogawa M, Takaishi M, Nakajima K, Kamijima R, Fujimoto C, Kataoka S, Terada Y, Sano S.
丂 Arthritis Rheumatol. 66(3):694-706, 2014. (IF:7.764)

11) Spondylodiscitis and Achilles tendonitis due to gout.
丂 Taniguchi Y1, Matsumoto T, Tsugita M, Fujimoto S, Terada Y.
丂 Mod Rheumatol. 24(6):1026-7, 2014. (IF:2.397)

12) CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells.
丂 Nishioka C, Ikezoe T, Yang J, Nobumoto A, Kataoka S, Tsuda M, Udaka K, Yokoyama A.
丂 Int J Cancer. 2014 Jan 1;134(1):55-64乮IF:5.085乯

13) Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.
丂 Nishioka C, Ikezoe T, Yang J, Nobumoto A, Tsuda M, Yokoyama A.
丂 Cancer Sci. 2014 Mar;105(3):297-307乮IF:3.523乯

14) Dienogest improves human leucocyte antigen-DR underexpression and reduces tumour necrosis factor-兛 production in peritoneal fluid cells from women with endometriosis.
丂 Maeda N, Izumiya C, Taniguchi K, Matsushima S, Mita S, Shimizu Y, Fukaya T.
丂 Eur J Obstet Gynecol Reprod Biol. 2014 Jun;177:48-51. 乮IF:1.695乯

15) Suppression of oxidative stress and 5-lipoxygenase activation by edaravone improves depressive-like behavior after
丂 concussion. 丂
丂 Higashi Y, Hoshijima M, Yawata T, Nobumoto A, Tsuda M, Shimizu T, Saito M, Ueba T.
丂 J Neurotrauma. 2014 Oct 15;31(20):1689-99乮IF:3.714乯

1) 堜忋峢曘丄帥揷揟惗
丂 媫惈擜嵶娗娫幙惈恡墛
丂 恡幘姵丒摟愅嵟怴偺帯椕2014-2016丄pp207-210丄撿峕摪丄搶嫗丄2014

2) 帥揷揟惗丄撨恵壚捗旤 丂
丂 戞7復恡丒斿擜婍宯丂54丂寣擜 丂
丂 戞2斉丂徢忬暿娕岇夁掱丄堜忋抭巕/堫悾捈旻曇廤丄pp922-927丄堛妛彂堾丄搶嫗丄2014

3) 慜揷挿惓 丂
丂 巕媨撪枌徢儊僇僯僘儉偵偍偗傞媡棳宱寣偲偦偺柶塽妛揑娔帇婡峔Decreased Immunosurveillance System in Peritoneal Cavity
丂 to Retrograde Menstruation in Women with Endometriosis 丂
丂 擔杮嶻壢晈恖壢妛夛嶨帍丄66乮12乯丄2895亅2902丄2014

崙撪妛夛

1) 戝弌壚庻丄扟岥媊揟丄徏杮棾婫丄搰懞朏巕丄弿曽岻擇丄堜忋峢曘丄杧栰懢榊丄惣嶳丂恑丄媑塱懽旻丄帥揷丂揟惗
丂 IgG4娭楢幘姵偺椪彴揑摿挜乮寣惔妛揑/夋憸強尒偺娭楢乯
丂 戞58夞擔杮儕僂儅僠妛夛憤夛丒妛弍廤夛儚乕僋僔儑僢僾丄4丄24-26丄2014丄丂丂搶嫗

2) 扟岥媊揟丄徏杮棾婫丄丂戝弌壚庻丄搰懞朏巕丄弿曽岻擇丄堜忋峢曘丄杧栰懢榊丄媑塱懽旻丄惣嶳丂恑丄岞暥丂媊梇丄彫椦栁恖丄
丂 帥揷揟惗
丂 BCG銷泖撪拲擖椕朄屻斀墳惈娭愡墛偺屻傠岦偒挷嵏
丂 戞58夞擔杮儕僂儅僠妛夛憤夛丒妛弍廤夛儚乕僋僔儑僢僾丄4丄24-26丄2014丄搶嫗

3) 杧栰懢榊丄帥揷揟惗
丂 AKI偺敪惗婡彉偲昦懺
丂 戞57夞擔杮恡憻妛夛妛弍憤夛丂丂僔儞億僕僂儉丄7丄4-6丄2014丄墶昹

4) 扟岥媊揟丄帥揷揟惗
丂 嫮捈惈愐捙墛偵偍偗傞夋憸恌抐朄偺憗婜恌抐傊偺娭傢傝
丂 擔杮愐捙娭愡墛妛夛戞24妛弍廤夛僔儞億僕僂儉S2丄10丄4丄2014丄戝嶃

5) 慜揷挿惓
丂 巕媨撪枌徢丄偦偺撲傪捛偆乗媡棳宱寣偲柶塽娔帇僔僗僥儉乗
丂 戞36夞擔杮僄儞僪儊僩儕僆乕僔僗妛夛妛弍島墘夛丄2014擭1寧24-25擔丄搶嫗

6) 攏応怢堢丄崟娾桾旤丄捑暎丄墹旘枥丄嶳壓棾岾丄搒棷塸旤丄崅愇岞巕丄捗揷夒擵丄憡椙桽曘丄慜揷挿惓
丂 僸僩鋊懷寣姴嵶朎偵偍偗傞働儌僇僀儞儗僙僾僞乕偺敪尰夝愅
丂 KMS儕僒乕僠儈乕僥傿儞僌丄2014擭2寧19擔-20擔丄崅抦

7) 捑暎丄攏応怢堢丄墹旘枥丄嶳壓棾岾丄搒棷塸旤丄曅壀嵅梍丄栴惗寬堦丄崅愇 岞巕丄崟娾桾旤丄捗揷夒擵丄憡椙桽曘丄慜揷挿惓
丂 儅僂僗偺枛徑寣姴嵶朎偐傜偺峈庮釃僄僼僃僋僞乕偺桿摫偍傛傃偦偺峈庮釃岠壥偺専摙
丂 戞13夞擔杮嵞惗堛椕妛夛憤夛丄2014擭3寧4擔-6擔丄嫗搒

8) 慜揷挿惓
丂 巕媨撪枌徢敪徢儊僇僯僘儉偵偍偗傞媡棳宱寣偲偦偺柶塽妛揑娔帇婡峔
丂 戞66夞擔杮嶻壢晈恖壢妛妛弍島墘夛丄2014擭4寧18-20擔丄搶嫗

9) 墹旘枥丄捑暎丄 嶳壓棾岾丄攏応怢堢丄搒棷塸旤丄捗揷夒擵丄慜揷挿惓丄憡椙桽曘
丂 怴惗巈擼嫊寣嵞燇棳忈奞儌僨儖儅僂僗偺妋棫偲摨庬摨宯銪嵶朎堏怉偺帋傒
丂 戞2夞鋊懷寣偵傛傞嵞惗堛椕尋媶夛丄2014擭7寧12擔丄搶嫗

10) 搒棷塸旤丄捗揷夒擵丄攏応怢堢丄 嶳壓棾岾丄墹旘枥丄捑暎丄慜揷挿惓丄憡椙桽曘
丂 鋊懷寣姴嵶朎偺枹暘壔惈堐帩攟梴偺帋傒
丂 戞2夞鋊懷寣偵傛傞嵞惗堛椕尋媶夛丄2014擭7寧12擔丄搶嫗

11) 慜揷挿惓
丂 巕媨撪枌徢偵傛傞晄擠徢偵懳偡傞撪帇嬀壓庤弍偺堄媊
丂 戞32夞 擔杮庴惛拝彴妛夛憤夛丒妛弍島墘夛丄2014擭7寧31擔-8寧1擔丄搶嫗

12) Tatsuyuki Yamashita, Keiko Nio, Kaoru Miyahara, Miho Satho, Masayuki Tsuda, Tomoki Kosugi, Kenji Kadomatsu,
丂 Koichi Honke
丂 Seminolipid is essential for the delivery of monocarboxylate transporter 4 (MCT4) to spamatogenic cells from Sertoli
丂 cells
丂 戞33夞擔杮摐幙妛夛擭夛丄2014擭8寧10擔-12擔丄柤屆壆

13) 慜揷挿惓
丂 巕媨撪枌徢敪徢偺撲傪扵傞乗媡棳宱寣偲暊峯撪柶塽僔僗僥儉傪拞怱偵乗
丂 戞67夞拞崙巐崙嶻壢晈恖壢妛夛丄2014擭9寧13-14擔丄嶳岥

14) 嶳壓棾岾丄恗旜宨巕丄媨尨奭丄捗揷夒擵丄嵅摗旤斂丄彫悪抭婯丄栧徏寬帯丄杮壠岶堦
丂 惛巕宍惉偵偍偗傞棸巁壔摐帀幙seminolipid偺婡擻夝柧
丂 戞87夞擔杮惗壔妛夛擭夛丄2014擭10寧15-18擔丄嫗搒

1) The impact of covariate distribution characteristics on the power in logistic regression models: a simulation study.
丂 Naoko Kumagai, Hiromi Kataoka,Yutaka Hatakeyama,Kohei Akazawa and Yoshiyasu Okuhara.
丂 Journal of Computations & Modelling. 2014:4(4)141-66.

2) Simulation Program to Determine Sample Size and Power for a Multiple Logistic Regression Model with Unspecified
丂 Covariate Distributions.
丂 Naoko Kumagai, Kohei Akazawa, Hiromi Kataoka, Yutaka Hatakeyama, Yoshiyasu Okuhara.
丂 Health. 6, 2973-2998, 2014

3) Prediction model for glucose metabolism based on lipid metabolism.
丂 Hatakeyama Y, Kataoka H, Nakajima N, Watabe T, Fujimoto S, Okuhara Y.
丂 Methods Inf Med. 2014;53(5):357-63. doi: 10.3414/ME14-01-0034. Epub 2014 Jul 2.(IF:2.248)

4) A hierarchical Bayesian framework to infer the progression level to diabetes based on deficient clinical data.
丂 Watabe T, Okuhara Y, Sagara Y.
丂 Comput Biol Med. 2014 Jul;50:107-15. doi: 10.1016/j.compbiomed.2014.04.017. Epub 2014 May 1.(IF:1.240)

5) KIF20A-mediated RNA granule transport system promotes the invasiveness of pancreatic cancer cells.
丂 Taniuchi K, Furihata M, Saibara T.
丂 Neoplasia. 2014 Dec;16(12):1082-93. doi: 10.1016/j.neo.2014.10.007. (IF 5.388)

6) IGF2BP3-mediated translation in cell protrusions promotes cell invasiveness and metastasis of pancreatic cancer.
丂 Taniuchi K, Furihata M, Hanazaki K, Saito M, Saibara T.
丂 Oncotarget. 2014 Aug 30;5(16):6832-45. (IF 6.63)

7) Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.
丂 Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T,
丂 Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, Okanoue T; Japan Study Group of
丂 NAFLD (JSG-NAFLD).
丂 World J Gastroenterol. 2014 Aug 7;20(29):10108-14. doi: 10.3748/wjg.v20.i29.10108. (IF 2.37)

8) Simultaneous occurrence of gastric lipoma and early gastric cancer.
丂 Namikawa T, Munekage E, Mizuta H, Kobayashi M, Saibara T, Hanazaki K.
丂 Endoscopy. 2014;46 Suppl 1 UCTN:E338-9. doi: 10.1055/s-0034-1377279. Epub 2014 Aug 4. (IF 5.05)

9) Safety and efficacy of image-guided enzyme-targeting radiosensitization and intraoperative radiotherapy for locally
丂 advanced unresectable pancreatic cancer.
丂 Nishioka A, Ogawa Y, Miyatake K, Tadokoro M, Nogami M, Hamada N, Kubota K, Kariya S, Kohsaki T, Saibara T,
丂 Okabayashi T, Hanazaki K.
丂 Oncol Lett.. 2014 Jul;8(1):404-408. Epub 2014 Apr 28. (IF 0.987)

10) RUVBL1 directly binds actin filaments and induces formation of cell protrusions to promote pancreatic cancer cell
丂 invasion.
丂 Taniuchi K, Furihata M, Iwasaki S, Tanaka K, Shimizu T, Saito M, Saibara T.
丂 Int J Oncol. 2014 Jun;44(6):1945-54. doi: 10.3892/ijo.2014.2380. Epub 2014 Apr 10. (IF 2.773)

11) Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1
丂 autoimmune hepatitis.
丂 Miyake Y, Yamamoto K, Matsushita H, Abe M, Takahashi A, Umemura T, Tanaka A, Nakamuta M, Nakamoto Y, Ueno
丂 Y, Saibara T, Takikawa H, Yoshizawa K, Ohira H, Zeniya M, Onji M, Tsubouchi H; Intractable Hepato-Biliary Disease
丂 Study Group of Japan.
丂 Hepatol Res. 2014 Dec;44(13):1299-307. doi: 10.1111/hepr.12305. Epub 2014 Mar 6. (IF 2.735)

12) Upper limit of normal serum alanine aminotransferase levels in Japanese subjects.
丂 Tanaka K, Hyogo H, Ono M, Takahashi H, Kitajima Y, Ono N, Eguchi T, Fujimoto K, Chayama K, Saibara T, Anzai K,
丂 Eguchi Y; Japan Study Group of Non-alcoholic Fatty Liver Disease (JSG-NAFLD).
丂 Hepatol Res. 2014 Nov;44(12):1196-207. doi: 10.1111/hepr.12293. Epub 2014 Feb 17. (IF 2.735)

13) Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a
丂 large retrospective cohort of Japanese patients.
丂 Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Ono M, Kawaguchi T, Imajo K, Aikata H, Tanaka S,
丂 Kanemasa K, Fujimoto K, Anzai K, Saibara T, Sata M, Nakajima A, Itoh Y, Chayama K, Okanoue T; Japan Study Group
丂 of Nonalcoholic Fatty Liver Disease.
丂 J Gastroenterol. 2014 Nov;49(11):1477-84. doi: 10.1007/s00535-013- 0911-1. Epub 2013 Nov 26. (IF 4.020)

14) Aromatase-null mice expressing enhanced green fluorescent protein in germ cells provide a model system to assess
丂 estrogen-dependent ovulatory responses.
丂 Toda K, Hayashi Y, Yamashita A, Okabe M, Ono M, Saibara T.
丂 Transgenic Res. 2014 Apr;23(2):293-302. doi: 10.1007/s11248-013-9771-y. Epub 2013 Nov 22. (IF 2.52)

15) Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine
丂 tumors.
丂 Hasegawa T, Yamao K, Hijioka S, Bhatia V, Mizuno N, Hara K, Imaoka H, Niwa Y, Tajika M, Kondo S, Tanaka T,
丂 Shimizu Y, Kinoshita T, Kohsaki T, Nishimori I, Iwasaki S, Saibara T, Hosoda W, Yatabe Y.
丂 Endoscopy. 2014 Jan;46(1):32-8. doi: 10.1055/s-0033-1344958. Epub 2013 Nov 11. (IF 5.05)

16) The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver
丂 disease.
丂 Taketani H, Sumida Y, Tanaka S, Imajo K, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Kanemasa K, Chayama K,
丂 Itoh Y, Yoshikawa T, Saibara T, Fujimoto K, Nakajima A; Japan Study Group of NAFLD.
丂 J Gastroenterol. 2014 Jul;49(7):1163-74. doi: 10.1007/s00535-013-0871- 5. Epub 2013 Aug 22. (IF 4.02)

17) Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice.
丂 Ono M, Ogasawara M, Hirose A, Mogami S, Ootake N, Aritake K, Higuchi T, Okamoto N, Sakamoto S, Yamamoto M,
丂 Urade Y, Saibara T, Oben JA.
丂 J Gastroenterol. 2014 Jun;49(6):1065-73. doi: 10.1007/s00535-013-0852-8. Epub 2013 Jun 26. ( IF 4.02)

18) Clinical efficacy of combination therapy with ME3738 and pegylated interferon-alpha-2a in patients with hepatitis C
丂 virus genotype 1.
丂 Saibara T, Enomoto N, Kaneko S, Chayama K, Sata M, Imawari M, Onishi S, Okita K.
丂 Hepatol Res. 2014 Apr;44(4):410-9. doi: 10.1111/hepr.12139. Epub 2013 Jun 20. (IF 2.735)

1) 媣曐嫓 丂丂丂丂丂丂丂
丂 壠懓楌偐傜恌抐偵帄偭偨挊柧怱旍戝傪掓偡傞僿僥儘愙崌懱偺1椺 丂
丂 乽僼傽僽儕乕昦徢椺廤vol. 1乮迨摗丂媊彑丂曇乯乿丄77-80暸丄Medical Tribune丄搶嫗丄 2014

2) 媣曐嫓 丂丂丂丂丂丂丂
丂 擇師惈怱嬝徢傪尒摝偝側偄 怱Fabry昦 丂
丂 擔杮撪壢妛夛嶨帍 戞103姫;293-298, 2014

3) 媣曐嫓丄杒壀桾復 丂丂丂丂丂丂丂
丂 嵍幒偺宍懺偱梊屻傪抦傞 丂
丂 乽椪彴怱晄慡偺偄偪偽傫戝帠側偲偙傠60乮嵅摗岾恖丂曇乯乿丄81-85暸丄姅幃夛幮儊僨傿僇弌斉丄戝嶃丄2014

崙撪妛夛

1) 杒壀桾復 丂丂丂丂丂
丂 堚揱惈怱嬝幘姵偺椪彴 丂丂丂丂丂
丂 戞62夞丂擔杮怱憻昦妛夛妛弍廤夛丂愬戜

2) 丂丂丂丂丂
丂 旍戝宆怱嬝徢偺昦懺偲偦偺椶帡幘姵娪暿偲偦偺椶帡幘姵娪暿偺廳梫惈 丂丂丂丂丂
丂 戞18夞擔杮怱晄慡妛夛丂戝嶃

1) 丂丂丂丂丂
丂 擔忢椪彴偵偍偗傞旍戝宆怱嬝徢傊偺傾僾儘乕僠 丂丂丂丂丂
丂 戞50夞擔杮撪壢妛夛巐崙抧曽夛惗奤嫵堢島墘夛丂摽搰

1) 愭抂堛椕妛僐乕僗傪棜廋偟偰偄傞堛妛壢4擭惗偑丄2013擭11寧偵恄屗偱奐嵜偝傟偨戞33夞堛椕忣曬妛夛楢崌戝夛偱敪昞偟偨乽恌
丂 椕僨乕僞儀乕僗傪梡偄偨Helicobacter pylori偵懳偡傞彍嬠棪偺曄壔偲彍嬠帯椕偵娭楢偡傞幘姵偺夝愅乿偑乽尋媶彠椼徿乿偵慖偽
丂 傟丄2014擭6寧6擔偵壀嶳偱奐嵜偝傟偨戞18夞 擔杮堛椕忣曬妛夛弔婫妛弍戝夛 乮僔儞億僕僂儉2014 in 壀嶳乯偱昞彶偝傟偨丅
丂

1) Mean lung pressure during adult high-frequency oscillatory ventilation: an experimental study using a lung model.
丂 Hirayama T, Nagano O, Shiba N, Yumoto T, Sato K, Terado M, Ugawa T, Ichiba S, Ujike Y.
丂 Acta Med Okayama. 2014 Dec;68(6):323-9. IF乮2014/2015乯丗0.696

2) Feasibility study of immediate pharyngeal cooling initiation in cardiac arrest patients after arrival at the emergency
丂 room.
丂 Takeda Y, Kawashima T, Kiyota K, Oda S, Morimoto N, Kobata H, Isobe H, Honda M, Fujimi S, Onda J, I S, Sakamoto
丂 T, Ishikawa M, Nakano H, Sadamitsu D, Kishikawa M, Kinoshita K, Yokoyama T, Harada M, Kitaura M, Ichihara K,
丂 Hashimoto H, Tsuji H, Yorifuji T, Nagano O, Katayama H, Ujike Y, Morita K.
丂 Resuscitation. 2014 Dec;85(12):1647-53. doi: 10.1016/j.resuscitation.2014.09.014. Epub 2014 Sep 28. IF乮2014乯丗
丂 4.167

3) Effect of preoperative carbohydrate loading on the management of blood glucose and body temperature.
丂 Yatabe T, Tamura T, Yokoyama M.
丂 J Anesth. 2014; 28: 148-51. (IF=1.176)

4) Prolonged post-dural puncture headache in a patient during treatment with selective serotonin reuptake inhibitor: a
丂 case report and animal experiment.
丂 Kawano T, Takahashi T, Kitaoka N, Yokoyama M.
丂 J Anesth. 2014; 28: 937-9. (IF=1.176)

5) Effects of ketoprofen for prevention of postoperative cognitive dysfunction in aged rats.
丂Kawano T, Takahashi T, Iwata H, Morikawa A, Imori S, Waki S, Tamura T, Yamazaki F, Eguchi S, Kumagai N,
丂 Yokoyama M.
丂 J Anesth. 2014; 28: 932-6. (IF=1.176)

6) Preventive effects of multisensory rehabilitation on development of cognitive dysfunction following systemic
丂 inflammation in aged rats.
丂 Kawano T, Morikawa A, Imori S, Waki S, Tamura T, Yamanaka D, Yamazaki F, Yokoyama M.
丂 J Anesth. 2014; 28: 780-4. (IF=1.176)

7) Influence of desflurane on postoperative oral intake compared with propofol.
丂 Yatabe T, Yamashita K, Yokoyama M..
丂 Asia Pac J Clin Nutr. 2014;23: 408-12. (IF=1.699)

8) A preliminary study of patients' perceptions on the implementation of the WHO surgical safety checklist in women
丂 who had Cesarean sections.
丂 Kawano T, Tani M, Taniwaki M, Ogata K, Yokoyama M.
丂 J Anesth. 2014; 28: 467-70. (IF=1.176)

挊彂

1) 挿栰廋
丂 HFOV乮崅昿搙怳摦姺婥乯
丂 屇媧椕朄丒屇媧娗棟偵偍偗傞 5 years 暥專丂儗價儏乕 2009-2013乮巵壠椙恖乯丄pp169-182丄崕惤摪弌斉丄
丂 搶嫗搒暥嫗嬫杮嫿丄2014擭

2) Kawano T.
丂 Peripheral Neuropathy: Capter 5
丂 A Current Overview of Diabetic Neuropathy - Mechanisms,Symptoms, Diagnosis, and Treatment.pp. 89-105.
丂 (ISBN 978-953-51-1451-2) Edited by Paulo Armada-Da-Silva, In Tech, 2014

3) 壨栰 悞丄 墶嶳 惓彯
丂 怴愴棯偵婎偯偔杻悓丒廃弍婜堛妛
丂 杻悓壢堛偺偨傔偺丂丂廃弍婜偺醬捝娗棟. 廃弍婜醬捝偺桳奞嶌梡丂柶塽宯傊偺嶌梡. pp 101-109. 拞嶳丂彂揦

4) 栴揷晹抭徍丄墶嶳惓彯丄壴嶈榓峅
丂 攕寣徢乮僙僾僔僗乯媬柦帯椕偺嵟慜慄乮抾枛丂朏惗曇乯
丂 12-2 寣摐僐儞僩儘乕儖乣恖岺鋁憻乣 259-265丄堛栻僕儍乕僫儖幮丄戝嶃丄2014

5) 壨栰 悞丄墶嶳惓彯
丂 峝枌慂巋屻摢捝
丂 捝傒恌椕僉乕億僀儞僩. 椪彴曇. G. 帯椕偵傛傞崌暪徢. 2014丄 p252. 暥岝摪丄搶嫗

6) 壨栰 悞丄墶嶳惓彯
丂 壔擽惈愐捙墛
丂 捝傒恌椕僉乕億僀儞僩. 椪彴曇. G. 帯椕偵傛傞崌暪徢. 2014丄 p253. 暥岝摪丄搶嫗

7) 墶嶳惓彯乮曇廤埾堳乯
丂 怴愴棯偵婎偯偔杻悓丒廃弍婜堛妛
丂 杻悓壢堛偺偨傔偺懱塼丒戙幱丒懱壏娗棟 拞嶳彂揦

8) 栴揷晹抭徍丄墶嶳惓彯
丂 徚壔婍昦恌椕丂戞2斉乮徚壔婍昦恌椕戞2 斉曇廤埾堳夛曇乯
丂 IV-2丂杻悓丂366-8丄堛妛彂堾丄搶嫗丄2014

1) 埨岝 儔償僃儖崄曐巕
丂 Prenatal/postnatal mental health and risk factors: family members and friends' roles in the cohort of the Japan
丂 Environment and Children's Study in Kochi Prefecture.
丂 SIGAMA THETA TAU INTERNATIONAL HONOR SOCIETY 2ND EUROPEAN REGIONAL CONFERENCE丂
丂 暯惉26擭6寧17擔丄儓乕僥儃儕丄僗僂僃乕僨儞

崙撪妛夛

1) 挿栰廋
丂 Pro-Con丗惉恖ARDS偵懳偡傞HFOV偼桳岠偐丠Pro偺棫応偐傜
丂 乽惉恖ARDS偵懳偡傞崅昿搙怳摦姺婥乮HFOV乯偺桳岠惈傪専徹偡傞偵偼偝傜側傞RCT偑昁梫偱偁傞乿
丂 戞41夞擔杮廤拞帯椕堛妛夛憤夛丄2014擭2寧27擔丄嫗搒巗

2) 挿栰廋
丂 僔儞億僕僂儉丗撿奀僩儔僼抧恔懳嶔 乽峀堟堛椕斃憲懳嶔乿
丂 擔杮杻悓壢妛夛戞61夞妛弍廤夛丄2014擭5寧16擔丄墶昹巗

3) 壨栰 悞
丂 ATP 姶庴惈K亄僠儍僱儖傪昗揑偲偟偨桳梡側幘姵帯椕丂丂愴棯偺敪揥. 恄宱ATP 姶庴惈K亄僠儍僱儖傪昗揑偲偟偨恄宱忈奞惈捝帯椕偺壜擻惈.
丂 戞87 夞擔杮栻棟妛夛擭夛.2014.3.19-21, 愬戜

4) 壨栰 悞
丂 Current pain research necessary and challenging.
丂 戞18 夞擔杮恄宱杻悓丒廤拞帯椕尋媶夛 2014.4.18-19 壂撽

5) 壨栰 悞
丂 廃弍婜娗棟偺QOR乮Quality of Recovery乯傪峫偊傞. 乽崅楊壔幮夛偵偍偗傞廃弍婜 乬Quality of Recovery (QOR)乭
丂 擔杮嬫堟杻悓丂妛夛戞1 夞妛弍廤夛.2014.4.25-26. 壀嶳

6) 壨栰 悞
丂 乽庤弍幒偱偺婋婡娗棟 - 撍慠偺婋婡偵丂丂娭偟偰傕杻悓壢堛偑僐儅儞僟乕偲側偭偰椻惷偵懳墳偡傞乿-廃弍婜傾僫僼傿儔僉僔乕丗丂
丂 媮傔傜傟傞恦懍側敾抐偲揔愗側懳墳傪抦傞-
丂 擔杮杻悓壢妛夛戞61夞妛弍廤夛2014. 5. 15-17. 墶昹

7) 栴揷晹 抭徍丄墶嶳 惓彯
丂 憗婜宱挵塰梴丒宱岥愛庢
丂 擔杮杻悓壢妛夛戞61夞妛弍廤夛 2014.5.15-17墶昹

8) 栴揷晹 抭徍丄墶嶳 惓彯
丂 廃弍婜丒廤拞帯椕椞堟偵偍偗傞寣摐娗棟偲恖岺鋁憻乚尰忬偲崱屻偺壽戣乚
丂 戞52 夞擔杮恖岺憻婍妛夛戝夛 2014.10.17-19 嶥杫

9) 栴揷晹 抭徍
丂 岆栻杊巭懳嶔偵偍偗傞僇儔乕僔儕儞僕偺栶妱
丂 擔杮椪彴杻悓妛夛 戞34夞戝夛丆2014.11.1-3搶嫗

10) 撿傑傝側
丂 偙偆偪僄僐僠儖挷嵏偺恑捇忬嫷
丂 暯惉25擭搙崅抦嶻壢晈恖壢妛夛媦傃崅抦導嶻晈恖壢堛夛掕椺憤夛丄暯惉26擭5寧24擔丄崅抦巗

11) 撿傑傝側
丂 巕偳傕偺寬峃偲娐嫬偵娭偡傞慡崙挷嵏乮僄僐僠儖挷嵏乯丗偙偆偪儐僯僢僩僙儞僞乕偵偍偗傞恑捇忬嫷
丂 暯惉26擭搙崅抦導彫帣曐寬嫤夛妛夛丄暯惉26擭8寧7擔丄崅抦巗

12) 悰徖 惉暥
丂 偙偆偪僄僐僠儖挷嵏偺恑捇忬嫷
丂 戞86夞擔杮彫帣壢妛夛崅抦抧曽夛丄暯惉26擭9寧28擔丄崅抦巗

12) 悰徖 惉暥
丂 偙偆偪僄僐僠儖挷嵏偺恑捇忬嫷
丂 戞86夞擔杮彫帣壢妛夛崅抦抧曽夛丄暯惉26擭9寧28擔丄崅抦巗

13) 埨岝儔償僃儖崄曐巕
丂 巕偳傕偺寬峃偲娐嫬偵娭偡傞慡崙挷嵏(僄僐僠儖挷嵏)丗崅抦儐僯僢僩僙儞僞乕偵偍偗傞恑捇曬崘丒峀曬媦傃僼僅儘乕傾僢僾偺
丂 庢傝慻傒偵偮偄偰
丂 擔杮撪暘斿奾棎壢妛暔幙妛夛(娐嫬儂儖儌儞妛夛)丂戞17夞尋媶敪昞丄 暯惉26擭12寧9擔丄搶嫗

14) 悰徖丂惉暥
丂 偙偆偪僄僐僠儖挷嵏偺儕僋儖乕僩婜娫偺傑偲傔偲崱屻偵偮偄偰
丂 戞64夞崅抦嶻壢晈恖壢妛夛妛弍廤夛丄暯惉26擭12寧13擔丄崅抦巗

1) 擔杮嬫堟杻悓妛夛戞1夞妛弍廤夛 嵟桪廏墘戣徿

2) 擔杮杻悓壢妛夛戞61 夞妛弍廤夛 嵟桪廏墘戣徿

3) 擔杮杻悓壢妛夛 戞51 夞 拞巐崙巟晹夛 妛弍廤夛 嵟桪廏墘戣徿

4) 擔拞杻悓摙榑夛 怴堜徿乮嵟桪廏墘戣徿乯

1) 儔僕僆曻憲(RKC儔僕僆)丗婥偵側傞寬峃僼傽儈儕乕僪僋僞乕
丂 乽嵭奞堛椕丗DMAT偵偮偄偰乿丄挿栰廋丄2014擭3寧3擔曻憲

2) 抧堟忣曬帍偼偨傕乣傜乮暯惉26擭1寧崋乯嶲壛幰6000恖
丂 偪傚傞傞傫僼僃僗僞僀儀儞僩崘抦丄暯惉26擭1寧

3) 嶨帍傎偭偲偙偆偪暿嶜乽崅抦昦堾僈僀僪乿 偪傚傞傞傫僼僃僗僞僀儀儞僩崘抦
丂 暯惉26擭1寧25擔

4) 戝妛峀曬帍崅抦戝妛峀曬帍Lead丂2014搤崋 嶲壛幰6000恖
丂 偪傚傞傞傫僼僃僗僞僀儀儞僩崘抦丄暯惉26擭1寧

5) 儔僕僆RKC崅抦曻憲儔僕僆丂乽傒傫側偺儔僕僆乿挷嵏偺恑捇丒嶲壛曞廤
丂 暯惉26擭1寧16擔

6) 僥儗價RKC崅抦曻憲丂乽RKC揱尵斅乿挷嵏偺恑捇僀儀儞僩崘抦
丂 暯惉26擭1寧16擔

7) 働乕僽儖僥儗價 崅抦働乕僽儖僥儗價乽Kochi丂on TV!乿丄暯惉26擭1寧25乣31

8) 儔僕僆 RKC崅抦曻憲儔僕僆乽媣曐揷僸儘僔偺婥暘偼忋乆!乿挷嵏偺恑捇丒嶲壛曞廤
丂 暯惉26擭1寧20擔

9) 怴暦乮挬姧乯崅抦怴暦丄僄僐僠儖挷嵏偵偮偄偰丒恑捇忬嫷丒曞廤婜娫3/31枠
丂 暯惉26擭2寧4擔

10) 僥儗價RKC崅抦曻憲丂乽偙偆偪eye亄乿偪傚傞傞傫僼僃僗僞奐嵜丄暯惉26擭2寧11擔

11) 働乕僽儖僥儗價崄撿働乕僽儖僥儗價丄挷嵏偺恑捇丂嶲壛曞廤 暯惉26擭2寧5乣31擔

12) 働乕僽儖僥儗價崄撿働乕僽儖僥儗價丄挷嵏偺恑捇丂嶲壛曞廤 暯惉26擭3寧1乣7擔

13) 儔僕僆RKC崅抦曻憲儔僕僆乽媣曐揷僸儘僔偺婥暘偼忋乆!乿挷嵏偺恑捇丒嶲壛曞廤
丂 暯惉26擭3寧10擔

14) 僥儗價 RKC崅抦曻憲乽偙偆偪eye亄乿挷嵏偺恑捇丂嶲壛曞廤
丂 暯惉26擭3寧28擔

15) KUTV僥儗價崅抦亀儂僢僩崘抦斅亁曻憲丄暯惉26擭4寧1擔

16) RKC崅抦曻憲亀偙偆偪eye亁丂戞84夞愒偪傖傫夛乮敠懡夛応乯曻憲
丂 暯惉26擭4寧29擔

17) 崅抦怴暦 挬姧丂戞84夞愒偪傖傫夛乮敠懡夛応乯宖嵹丄暯惉26擭4寧30擔

18) 僄僼僄儉崅抦亀偪傚傞傞傫僗僥乕僔儑儞亁戞1夞乣22夞曻憲
丂 暯惉26擭5寧乣暯惉27擭3寧

19) RKC儔僕僆亀偡偙傗偐2014亁庢嵽丄暯惉26擭7寧26擔

20) 傎偭偲偙偆偪亀儅儅偺杮亁宖嵹丄暯惉26擭9寧25擔

21) 崅抦怴暦乽徻嵶挷嵏娫傕側偔巒傑傞両乿婰帠宖嵹丄暯惉26擭11寧28擔

22) RKC崅抦曻憲丄偝傫偝傫TV丄KUTV僥儗價崅抦丄NHK
丂 乽徻嵶挷嵏偑巒傑傝傑偟偨乿僯儏乕僗曻憲丄暯惉26擭12寧4擔

23) 崅抦怴暦乽徻嵶挷嵏偑巒傑傝傑偟偨乿婰帠宖嵹丄暯惉26擭12寧5擔

24) RKC崅抦曻憲丄RKC儔僕僆亀RKC巕堢偰墳墖抍亁CM曻憲
丂 暯惉26擭12寧20擔乣暯惉27擭1寧12擔

1) Less deep vein thrombosis due to transcutaneous fibular nerve stimulation in total knee arthroplasty: a randomized
丂 controlled trial.
丂 Izumi, M. Ikeuchi, K. Aso, N. Sugimura, Y. Kamimoto, T. Mitani, T. Ueta, T. Sato, M. Yokoyama, T. Sugiura, T. Tani.
丂 Knee Surg Sports Traumatol Arthrosc. 2014 (IF3.053)

崙撪妛夛

1) 寠嶳婱巏丄堜尨棟奊丄惵栘悞峢丄媨嶈椓暯丄愳杮忢嫪丄壀揷峗怶丄淎嫶寬懢榊丄晲搰抭棽丄媣暷婎旻丄搉嫶榓惌
丂 3D-CT偺懱昞柺捈愙搳塭朄偵傛傞怴偟偄僀儊乕僕僈僀僪屇媧婍奜壢庤弍
丂戞31夞擔杮屇媧婍奜壢妛夛憤夛丄2014擭5寧29擔亅30擔丄搶嫗

1) Outcome evaluation of an intervention to improve the effective and safe use of meropenem.
丂 Yagi Y, Okazaki M, Higaki H, Nakai M, Hirata A, Miyamura M.
丂 Int J Clin Pharm. 2014 Jun;36(3):648-56.(IF:1.348)

2) S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
丂 Okabayashi T, Shima Y, Iwata J, Morita S, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, Kosaki T, Kobayashi M,
丂 Hanazaki K.
丂 World J Surg. 乮IF 2.642 (2014)乯. 2014 Nov;38(11):2986-93.

3) Donepezil can improve ischemic muscle atrophy by activating angiomyogenic properties of satellite cells.
丂 Noguchi T, Kakinuma Y, Arikawa M, Okazaki K, Hoshino E, Iiyama T, Kubo T, Kitaoka H, Doi Y, Sato T.
丂 Circ J. 乮IF 3.94 (2014)乯2014;78(9):2317-24.

4) Extrahepatic stem cells mobilized from the bone marrow by the supplementation of branched-chain amino acids
丂 ameliorate liver regeneration in an animal model.
丂 Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Iiyama T, Tokumaru T, Namikawa T, Sugimoto T, Takezaki Y, Maeda
丂 H, Kobayashi M, Hanazaki K.
丂 J Gastroenterol Hepatol. 乮IF 3.504 (2014)乯 2014 Apr;29(4):870-7.

5) Surgical outcomes for 131 cases of carcinosarcoma of the hepatobiliary tract.
丂 Okabayashi T, Shima Y, Iwata J, Iiyama T, Sumiyoshi T, Kozuki A, Tokumaru T, Hata Y, Noda Y, Morita M.
丂 J Gastroenterol. 乮IF 4.523 (2014)乯 2014 Jun;49(6):982-91.

崙嵺妛夛

1) Miyamura M
丂 Medical aspects of Goishi-tea
丂 Internationl Symposia on Resarch towards Green Innovation 2014.1.12, Chiang Mai, THAILAND

崙撪妛夛

1) 斞嶳 払梇
丂 乽堛巘庡摫帯尡偺奣梫偲恑傔曽丗醶澒惈敪惡忈奞偵懳偡傞A宆儃僣儕僰僗撆慺帯椕傪捠偟偰乿
丂 擔杮婥娗怘摴壢妛夛僔儞億僕僂儉S1乽婥娗怘摴壢偐傜敪怣偡傞怴婯堛椕乿丂2014擭11寧13擔乮栘乯崅抦

庴徿

1) 暯惉26擭搙丂尋媶尠彶惂搙丂戝妛堾惗尋媶彠椼徿丂敧栘桽彆

2) 暯惉26擭搙丂崅抦戝妛堛妛晹晬懏昦堾丂庒庤桪廏尋媶幰徿丂敧栘桽彆